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SUMMARY OF RECOMMENDATIONS 
General 
1. The supply of PBS medicines to RAAHS through S100 has substantially 
increased medicines access to the Aboriginal and Torres Strait Islander population 
in RRMA 6-7 regions, and should continue to be the predominant form of 
medicines supply to these services.  
2. Despite the gains in PBS utilisation from the S100 program, NACCHO does not 
believe that current expenditure in the S100 program is sufficient to meet 
Aboriginal people’s health needs. PBS utilisation may need to increase 
substantially (and exceed that for the non-Aboriginal population) to address the 
three times higher rate of death before age 65 years. 
CTG Scripts and S100 supply 
3. At present, remote area ACCHSs cannot offer clients both CTG scripts and PBS 
medicines under S100 (Table 3). Where a community pharmacy and private 
general practice are located in RRMA 6-7 regions, Aboriginal and Torres Strait 
Islander patients no longer need to attend a RAAHS or ACCHS to receive 
affordable medicines. Increased affordability is important, but as vehicles for 
improving patient’s medication adherence and QUM, ACCHSs provide 
significant advantages over private general practices (see TOR(c)). It is preferable 
for Aboriginal and Torres Strait Islander patients to have access to QUM 
supports.  
a. ACCHSs in RRMA 6-7 locations should therefore be given the option of 
also providing CTG scripts to clients as well as the option to stock 
medicines on site through the S100 program. 
Financing Dose Administration Aids 
4. Affordability is a major factor influencing Aboriginal people’s equitable access to 
medicines and by addressing that, the S100 supply program has accomplished 
significant gains towards equity. Medication adherence is also influenced by a 
range of other factors and can be enhanced through QUM strategies (see TOR (c)) 
including dose administration aids (DAA’s). The S100 Program does not provide 
funding support for DAA’s and many ACCHSs pay for these through their core 
budgets. 
a. NACCHO believes it is vital that financing for DAA’s to Aboriginal 
clients of remote area ACCHSs be supported in order to improve 
Aboriginal people’s medication adherence.  
5. DAAs for remote area ACCHSs may be financed through: 
a. a program such as QUMAX extended nationally, and/or other DAA 
program financed by extension to the 5th Community Pharmacy 
Agreement.  
b. a DAA service similar to that provided by the Department of Veterans 
Affairs (DVA) for eligible clients funded by the Australian Government. 
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c. specific QUM related grants (a service-specific QUM budget including for 
DAAs) to ACCHSs. See TOR (c).  
Quality Use of Medicine involving RAAHSs 
6. The S100 supply of medicines to ACCHSs has evolved to encompass a range of 
ancillary programs that support the quality use of medicines (QUM) in RAAHSs. 
The often unconnected nature of these programs adds to their complexity for 
primary health care services. These programs need better integration within 
primary health care.  
a. This can be achieved by the introduction of a scheme to allocate QUM 
budgets to remote area ACCHSs from which services can draw from, and 
negotiate service-specific activities with community pharmacy or 
academic pharmacists.  
b. The difference between the S100 program handling fee ($2.79) and the 
PBS dispensing fee ($6.42) per item comprises a PBS underspend that 
could be used to fund a range of service specific QUM initiatives within 
remote area ACCHSs. 
Governance of S100 supply and related QUM programs 
7. Governance for the broad range of QUM programs established to support 
RAAHSs in the S100 program needs to be improved.  
a. This will require the establishment of a broader and multidisciplinary 
steering committee structure that has significant NACCHO membership, 
but also includes the involvement of a range of pharmacy groups.  
b. In addition, consideration should be given to integrating or creating cross 
membership between remote-area QUM governance structures with 
governance committees responsible for QUMAX and the CTG PBS co-
payment relief measure (CTG scripts).  
c. NACCHO should be invited to be a member of a governance structure to 
monitor the implementation, uptake and evaluation of the CTG scripts 
measure, especially in the disaggregation of data between ACCHSs and 
private general practices.  
Pharmacist employment within RAAHSs 
8. Multiple independent reviews have confirmed that a greater level of pharmacist 
involvement in RAAHSs is needed. RAAHSs should be supported to employ 
salaried and sessional positions for pharmacists alongside other primary care staff.  
a. This can be achieved by transferring responsibility for the payment of 
QUM related pharmacist services to RAAHSs, as they move towards 
adopting pharmacists as core members of the primary health care team. 
Funding sources for these positions needs to be agreed upon and a range 
of options considered.  
b. NACCHO recommends that ‘pharmacists’ be added as additional allied 
health professionals under the Practice Nurse Incentive Program (PNIP). 
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This will provide the option for ACCHSs to (partly) fund a pharmacist (in 
any location across Australia).  
c. Introduce Medicare Rebates for the delivery of pharmacist services within 
ACCHSs (remote and non-remote) in recognition of their role within the 
primary health care team. This would support the full/part-time 
employment of pharmacists to undertake QUM related services and 
training. 
d. QUM Budgets to ACCHSs could be used to supplement the employment 
of sessional pharmacists.  
e. By expanding existing workforce related schemes, funding provision 
could be made for more academic pharmacist employment within remote-
area ACCHSs. Examples of schemes include the Rural Pharmacy 
Workforce Program under the 5th Community Pharmacy Agreement; and 
amendments to the Practice Nurse Incentive Program (by introducing 
pharmacists into the allied health professional category). 
Reimburse RAAHSs for dispensing S100 medicines  
9. Introduce a scheme for Medicare Australia to reimburse RAAHSs for dispensing 
S100 medicines to their clients. The labeling and dispensing activity of RAAHSs 
is currently not reimbursed. ACCHSs undertake and fund this activity from core 
service budgets. Funding received under such a scheme could be used towards 
QUM activity. 
A coordinated and systematic approach to QUM support 
10. Introduce a coordinated and systematic approach to QUM ‘systems support’ 
within remote-area ACCHSs by enabling service-specific initiatives through 
QUM Budgets and online QUM workplan development.   
a. QUM budgets (see above) could be used to subsidise the purchase of 
labeling equipment or provide QUM training of ACCHSs staff, or employ 
sessional pharmacists (or other uses of a service-specific QUM allocation- 
see Box 3). 
b. Regional or State/Territory ‘QUM Pharmacists’ could be employed within 
Affiliates or by the Guild (as per the QUMAX Program) to provide local 
support to remote area ACCHSs in developing service-specific QUM 
workplans and allocating their QUM budgets. Such an approach would 
need further consultation with NACCHO, taking into account the role of 
pharmacists employed locally by ACCHSs.  
c. A systematic and online approach to remote-area QUM workplan 
development would improve transparency, enhance workforce support, 
help ACCHSs to manage a service-specific QUM related budget, improve 
accountability and Departmental feedback to ACCHSs, and provide more 
tools to help guide services in the specification of the QUM services they 
need at a local level.  
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d. The successes achieved with QUMAX may help inform the systematic 
application of improved administration and monitoring towards QUM 
within ACCHSs participating in the S100 program.  
e. The implementation of an improved administration and monitoring system 
towards QUM within ACCHSs would require a full time position to be 
funded within NACCHO to facilitate the establishment of the above 
quality assurance system.  
Legislative amendments 
11. NACCHO encourages the Senate Committee to recommend legislative 
amendments to: 
a. Overcome the current prohibition to dispensing/filling of Dose 
Administration Aids (DAA) by pharmacists outside a community 
pharmacy. (eg Registering remote health clinics as ‘pharmacy outstations’ 
was one suggestion, but the feasibility and acceptability of that would 
need investigation). 
b. Align, simplify and revise State Health Poisons Acts and Pharmacy 
Practice Acts legislation so that barriers in the provision of pharmacy/ist 
services faced by RAAHSs can be addressed.  
12. RAAHSs are required (under S100 supply) to dispense and label PBS medicines, 
and this function should therefore be supported by a QUM-related service-specific 
budget (see TOR (c)).   
13. Legislative reform and QUM-budgets would assist staff within ACCHSs to 
undertake their required responsibilities towards dispensing and quality use of 
medicines. (See TOR(c)) 
Aboriginal Health Worker education and better communication with 
RAAHSs 
14. The employment of pharmacists within ACCHSs (see TOR(c)) would enhance 
educational opportunities for AHWs towards roles as Medication Assistants or the 
completion of Cert IV AHW Training. 
15. NACCHO believes that the substantial communication gap that prevents remote 
area ACCHSs from learning of the outcome of S100 support allowance 
workplans, and prevents feedback to the Department of Health and Ageing 
regarding the S100 supply program, can be resolved by the adopting the 
recommendations pertaining to TOR(c). 
PBS medicines listing for Aboriginal peoples and Torres Strait Islanders 
16. NACCHO continues to support the evidence-based listing of medicines in the 
PBS specifically for the Aboriginal and Torres Strait Islander population.  
NACCHO encourages the Department to invite NACCHO to consult with 
ACCHSs regarding any additional medicines that might be added to the PBS for 
this specific population. 
  7
Submission from the National Aboriginal Community Controlled Health Organisation, June 2011 
1.0 Introduction 
Special arrangements exist for the supply of pharmaceutical benefits to clients of eligible 
Remote Area Aboriginal Health Services (RAAHS), primarily due to Aboriginal peoples 
and Torres Strait Islanders having by far the worst health outcomes and the clearest 
inequity in health care provision of any identifiable group in the Australian population. 
These special arrangements for access to Pharmaceutical Benefits Scheme (PBS) 
medicines – based on Section 100 of the National Health Act (1953) – aim to alleviate 
these disadvantages, and assist in ‘Closing the Gap’ (CTG) between Aboriginal and other 
Australians.  
Currently 173 RAAHSs participate in the Section 100 program (Table 1) with the vast 
majority being State/Territory Government-run Aboriginal Health Services. Currently, 
only one third (34%) of participating RAAHSs are Aboriginal Community Controlled 
Health Services (ACCHSs).  
There are over 150 ACCHSs across Australia that are members of the National 
Aboriginal Community Controlled Health Organisation (NACCHO).  ACCHSs are 
distinct from State/Territory Government RAAHSs, and private general practices in that 
they are governed by an Aboriginal body which is elected by the local Aboriginal 
community and are not for profit services. By definition, ACCHSs deliver culturally 
appropriate and comprehensive primary health care to the community which controls it. 
A total of 23 community pharmacists currently support the S100 supply program.   
 
Table 1. Number of Remote Area Aboriginal Health Services (RAAHS) currently 
accessing medicines under Section 100 (National Health Act, 1953)1 
State/Territory Aboriginal Community 
Operated (ACCHSs) 
State/Territory 
operated 
Total 
NSW 5 - 5 
NT 25 54 79 
Qld 5 39 44 
SA 5 2 7 
Tas 2 - 2 
WA 17 19 36 
Total  59 114 173 
Source: Department of Health and Ageing. Athough approved, some services may elect not to participate, 
or may participate on an intermittent basis.  
 
NACCHO has systematically responded to each of the Terms of Reference detailed in the 
inquiry. The Section 100 arrangements of the Act are referred to as the ‘S100 Program’ 
or ‘S100 supply program’ hereafter. 
 
                                                            
1 Personal communication to Dr Couzos (May 2011). 
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2.0 NACCHO responses to the Terms of Reference 
The Senate Inquiry examines the following terms of reference, which are followed by 
responses from NACCHO. 
(a) whether these arrangements adequately address barriers experienced by 
Aboriginal and Torres Strait Islander people living in remote areas of Australia  
in accessing essential medicines through the PBS; 
This submission refers to the S100 Program with respect to its effectiveness in improving 
medicines supply (through co-payment relief and bulk supply on site within RAAHSs) 
and quality use of medicines (through ancillary programs (see TOR (c)).  
It is well established that the Section 100 arrangements of the National Health Act 1953 
for RAAHSs which commenced in 1999 significantly address barriers to access to all 
listed PBS medicines, for all clients (Aboriginal and non-Aboriginal) of RAAHSs, by 
eliminating the known barrier of cost. PBS medicines listed under S100 are provided at 
no cost, and without the need of a script, to clients in remote locations, with ‘remote 
locations’ constituting RRMA locations 6 and 7 (remote and very remote).  These 
locations denote a “very restricted accessibility of goods, services and opportunities for 
social interaction”.2  
These arrangements eliminate the need for a client to pay any ‘co-payment’ for medicines 
and bulk orders by RAAHSs mean that stocks of medicines are kept on site, eliminating 
the need for a prescription.  The pharmacist is reimbursed for bulk orders by Medicare 
but this excludes branded products (as Medicare only pays the generic cost of the 
medicine). When a generic medicine is out of stock, a pharmacy may absorb the brand 
price premium or some arrangement is made with the RAAHS.  
In non-remote areas, prescriptions presented to a pharmacy under section 85 of the 
National Health Act 1953 incur a co-payment of $34.20 for general patients and a co-
payment of $5.60 for concession card holders (Table 2, 1st Jan 2011).  
Two other programs have also provided co-payment relief for the Aboriginal and Torres 
Strait Islander population. A program known as QUMAX -Quality Use of Medicines 
Maximised for the Aboriginal and Torres Strait Islander population- has provided co-
payment relief to ‘needy’ Aboriginal and Torres Strait Islander patients of non-remote 
ACCHSs since 2008 until July 2010, this relief was extended to similar patients of 
private general practices (regardless of geographic location- Table 2) known as the PBS 
CTG Co-payment relief measure.3 (A description of the different sources of co-payment 
relief for the Aboriginal and Torres Strait Islander population and how they intersect with 
the S100 program is provided below). 
                                                            
2 Commonwealth Department of Health and Aged Care. Measuring Remoteness: Accessibility/Remoteness 
Index of Australia (ARIA). Canberra (ACT): Department of Health and Aged Care & the National Key 
Centre for Social Applications of Geographical Information Systems (GISCA) at the University of 
Adelaide; 2001 Oct. 21 p.  
3 Couzos S, Sheedy V, Thiele D. Improving Aboriginal and Torres Strait Islander people’s access to 
medicines — the QUMAX program. MJA Rapid online publication 21 June 2011. 
http://www.mja.com.au/public/issues/195_02_180711/cou10504_fm.html 
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S100 Program- Improved medicines access by PBS utilisation and expenditure 
Strong evidence that the S100 scheme addresses barriers to medicines access can be 
found in the comprehensive Co-operative Research Centre for Aboriginal Health’s 2004 
Review, which found that the program: 
“resulted in increased access to medicine in all jurisdictions. There was increased 
access to oral hypoglycaemics, ACE inhibitors, asthma medicine and acute 
medicines. These medicines are all used to treat conditions that are particularly 
problematic in the Aboriginal and Torres Strait Islander community. … The 
program has fostered the development of stronger relationships between 
pharmacists and [RAAHSs], and this has had benefits in terms of improving 
QUM (Quality use of Medicines) and the ability of [RAAHS] to provide 
integrated care. Overall S100 has been a very successful program and all 
respondents supported its continued funding”.4  
Medicines utilisation data showed strong evidence of increased PBS claims with 
progressive increases in the total number of quantities (of medicines) claimed per person 
(between 2000-03). In the 2000/01 to 2001/02 financial year, growth in the utilisation of 
ACE Inhibitors (for blood pressure) under the S100 program was twice the growth seen 
in PBS utilisation overall. Survey of pharmacists and services further confirmed 
increased PBS utilisation. The Review concluded that increased use rather than increased 
wastage was largely responsible for increased utilisation findings.  
Recent AIHW analysis confirms that PBS utilisation has significantly improved over the 
years for patients of RAAHSs. PBS per person expenditure over 2006-07 in remote/very 
remote regions of Australia was higher for Aboriginal peoples than non-Aboriginal ($223 
compared with $200, ratio 1.12).  
In comparison, Aboriginal peoples in non-remote regions have significantly less access to 
the PBS than the non-Aboriginal population. Over the 2006-07 financial year, for every 
dollar spent on medicines for a non-Aboriginal person, only 44 cents to 63 cents was 
spent on an Aboriginal person in these regions.   
Moreover, Aboriginal peoples in non-remote areas also had less access to the PBS than 
Aboriginal peoples in remote Australia (ratio 0.71 in major cities compared with S100 
regions).5 
The higher rate of medicines utilisation in remote Australia by Aboriginal peoples 
(exceeding that of non-Aboriginal peoples in that region and that of Aboriginal peoples in 
                                                            
4 Kelaher M, Taylor-Thomson D, Harrison N, O’Donoghue L, Dunt D, Barnes T & Anderson I. Evaluation 
of PBS Medicine Supply Arrangements for Remote Area Aboriginal Health Services Under S100 of the 
National Health Act. Melbourne (VIC): Co-operative Research Centre for Aboriginal Health & Program 
Evaluation Unit, University of Melbourne; 2004. 26 p.  
5 Australian Institute of Health and Welfare 2010. Expenditure on health for Aboriginal and Torres Strait 
Islander people 2006–07: an analysis by remoteness and disease. Health and welfare expenditure series no. 
40. Cat. no. HWE 49. Canberra: AIHW 
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major cities), is the reverse of what is expected and can be attributed to the success of the 
S100 supply program.  
Figure 1 outlines the five-year trend in PBS expenditure by geographical location and by 
Aboriginality. It demonstrates the above findings in S100 regions, but also shows that 
over 5 years to 2006-07, gains towards parity have been made especially in remote 
Australia.  
In non-remote regions, disparities in access to PBS medicines between Aboriginal and 
non-Aboriginal Australians continue to exist.  Geographically disaggregated data since 
2007 have not yet been released by the AIHW, however, we expect to see improvements 
in PBS access as a result of QUMAX (see below). 
 
Figure 1. Five year trend in PBS expenditure by Aboriginality and by geographical 
location (2001-2 to 2006-07).6 
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Note: S100 eligible locations are classified as ‘remote/very remote’. 
 
Despite the gains in PBS utilisation from the S100 program, NACCHO does not believe 
that current expenditure in the S100 program is sufficient to meet needs. 
Achieving parity in PBS medicines utilisation alone will not lead to a closing of the gap 
in health disparity between the Aboriginal peoples and other Australians. Higher per 
person PBS expenditure is required to address the three times higher rate of chronic 
disease affecting Aboriginal peoples. Aboriginal peoples are three times more likely to 
die before the age of 65 years than non-Aboriginal Australians. (66% of Aboriginal and 
Torres Strait Islander deaths occurred before the age of 65 years compared with 20% of 
                                                            
6 Extracted by Couzos S. Some caution in comparing PBS per capita AIHW with years preceding 2006-07. 
Different methodology in 2006-07, relying on the Voluntary Indigenous Identifier. (Source: Australian 
Institute of Health and Welfare 2010. Expenditure on health for Aboriginal and Torres Strait Islander 
people 2006–07: an analysis by remoteness and disease. Health and welfare expenditure series no. 40. Cat. 
no. HWE 49. Canberra: AIHW).  
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non-Indigenous deaths). Nearly 80% of the mortality gap (in terms of potential years of 
life lost) could be attributed to the higher burden of chronic diseases.7 
Expenditure towards the S100 Program has increased from $4 million in 1999-00 to $32 
million in 2007-08.8 With 127,400 Aboriginal peoples living in remote and very remote 
regions (at June 2006), $32 million provides the same level of PBS utilisation if these 
patients used medicines to the same degree as other Australians.9  
This indicates uptake of medicines (and expenditure) under the S100 program is still 
insufficient to meet the remote Aboriginal population’s needs, given that medicine 
requirements are likely to be much higher than other Australian’s. 
 
Other Co-Payment Relief Schemes 
Aboriginal and Torres Strait Islander patients in remote locations can now access 
medicines and receive co-payment relief in other ways, not just through S100 program. 
Aboriginal and Torres Strait Islander patients in remote areas can access co-payment 
relief not only from RAAHSs (S 100) but also from ‘Indigenous PIP’ registered private 
general practices (GPs) anywhere in Australia:  
• Between November 2008 and 30 June 2010, some remote-area patients visiting non-
remote ACCHSs could also access co-payment relief through the QUMAX Program.  
• From 1st July 2010, private GPs in remote and non-remote locations can now offer co-
payment relief (CTG scripts) if they are registered with the Indigenous Practice 
Incentive Payment (PIP). 
• From 1st July 2010, ACCHSs (including other designated Indigenous Health Services) 
can offer co-payment relief (CTG scripts) but only in non-remote locations and do not 
need to be registered with the Indigenous PIP.  
QUMAX 
QUMAX was developed jointly by the Pharmacy Guild of Australia and the National 
Aboriginal Community Controlled Health Organisation under the 4th Community 
Pharmacy Agreement in 2006-07. It commenced a program of intensive QUM support, 
provision of dose-administration aids (DAA’s), transport support and co-payment relief 
in 2008 until 30 June 2010, in non-remote ACCHSs. Thereafter, the co-payment relief 
function was transferred to the PBS co-payment relief measure (CTG scripts). QUMAX 
                                                            
7 AIHW. The health and welfare of Australia’s Aboriginal and Torres Strait Islander people. 2011 
8 AHCA review 
9 With 170 RAAHSs in 2007-08, $32 million amounts to only $188,235 per service per year. Using the per 
capita expenditure on PBS medicines for non-Indigenous Australians at $290 (2006-07), this means that 
649 persons per RAAHS (110,330 patients) may have benefited, which equates (roughly) to the Aboriginal 
population. 
  12
Submission from the National Aboriginal Community Controlled Health Organisation, June 2011 
continues to provide DAA’s and substantial QUM support to 2015 under the 5th 
Community Pharmacy Agreement.10 
QUMAX has been highly successful at increasing medicines access for ‘needy’ and 
disadvantaged Aboriginal peoples11 by eliminating co-payment across 70 ACCHSs in non-
remote locations.  
Between November 2009 and April 2010, the proportionate increase in the number of PBS 
medicines dispensed to patients of non-remote ACCHSs was nearly five times greater than 
the increase in medicines dispensed to all Australians, and exceeded the increase seen in 
remote areas (S100) by a factor of seven.  
Greater access to medicines for chronic disease (lipid-lowering, antihypertensive and 
asthma medications) accounted for most of the increase. These outcomes were achieved 
despite QUMAX operating on a capped budget per ACCHSs. 
Both the S100 program and QUMAX provide substantial evidence that co-payment relief 
has a significant impact in achieving equity in medicines access. Co-payment relief 
works, whether it’s through S100 supply (remote areas), or through scripts that are 
annotated to waive the co-payment (non-remote areas).  
QUMAX has also substantially increased medicines adherence and QUM within these 
ACCHSs according to an independent review.12 These QUM support functions are 
continuing (see also (c)). 
 
PBS Co-payment Relief Measure (CTG Scripts) 
The PBS Co-payment relief measure under the Indigenous Chronic Disease Program is 
based on a patient’s self-identified ethnicity; i.e. identifying as Aboriginal or Torres Strait 
Islander (but not requiring a three-tiered definition of Aboriginality).13 Under this 
measure, patients identifying as Aboriginal or Torres Strait Islander can be registered 
                                                            
10Couzos S, Sheedy V, Thiele D. Improving Aboriginal and Torres Strait Islander people’s access to 
medicines — the QUMAX program. MJA Rapid online publication 21 June 2011. 
http://www.mja.com.au/public/issues/195_02_180711/cou10504_fm.html 
11 Eligibility criteria: [The prescriber must be of the view] that significant adverse health outcomes may 
result from the failure of the person to take the prescribed medicine, and the person is unlikely to comply 
with their medicines regime without assistance; and c) either: i. the person is currently holding a 
concessional entitlement card for PBS benefits, or is eligible to receive such benefits; Or ii. the person is 
not currently holding a concessional entitlement card for PBS benefits, and is not eligible to receive such 
benefits, but the clinical consultation with a prescriber indicates one of the following sub-criterion are met: 
− a history of evidence of foregoing medicines; − evidence that health is failing because of non-compliance 
with medicines; − social and/or legal obligations for a large family including guardianship of children; or − 
existence of co-morbidities and need for three or more prescribed medicines. 
12 Urbis Pty Ltd for the Australian Government Department of Health and Ageing. Evaluation of the 
Quality Use of Medicines Maximised for Aboriginal and Torres Strait Islander People (QUMAX) Program. 
April 2011. 
http://www.health.gov.au/internet/main/publishing.nsf/Content/5B1B138DA00BB9C7CA2578150083984
E/$File/Final%20Report%20QUMAX%20Evaluation%20April%202011.pdf (accessed Jun 2011). 
13 Couzos S, Thiele D. The new “Indigenous health” incentive payment: issues and challenges. MJA 2010; 
192 (3) 154-157. 
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with Medicare Australia to participate in this program, through either: a private general 
practice registered with the Indigenous Practice Incentive Program (PIP) and living 
anywhere in Australia; or an ‘Indigenous Health Service’14, if the service is in a non-
remote area.  
Once PIP registered, the general practice receives an incentive payment from Medicare 
Australia, and if the patient is deemed eligible,15 they can have their PBS scripts 
annotated ‘CTG’ (Close the Gap), to receive either free medicines or significantly 
reduced co-payments for medicines (for the life of the Program, Table 2).  
 
Table 2. Summary of the medicinal concessions available to Aboriginal peoples and 
Torres Strait Islanders under the PBS co-payment measure (CTG scripts): 
Patients Concession Status 
 
Patient co-payment per PBS medicine 
Concession card holder 
 
Nil (free) Aboriginal & Torres Strait 
Islander (any age, who are 
at risk of chronic disease 
or have a chronic disease)  General $5.60 (free after SN threshold reached) * 
Concession card holder 
 
$5.60 All other Australians  
General $34.20 
*Aboriginal/Torres Strait Islander co-payment contributions are counted towards the Safety-Net (SN) as if 
they were general contributions (ie $34.20). Once the SN threshold is reached ($1317.20, equivalent to 
around 38 single item scripts per annum), Aboriginal and Torres Strait Islander general recipients receive 
free medicines for the remainder of the year as if they were concessional card holders.     
 
Difference between S100 supply program and CTG Scripts 
There are substantial differences between schemes in terms of policy and operational 
aspects, as well as differences in the way S100 program operates between jurisdictions.16  
The main difference is that CTG scripts are merely annotated prescriptions that provide 
financial concessions for Aboriginal clients, but not linked to QUM programs. The S100 
                                                            
14‘Indigenous Health Service’ is the terminology adopted by COAG. It pertains to ACCHSs, other OATSIH 
funded and State/Terr funded AHS’s as well as private general practices that may be identified as such.   
15 Eligibility criteria: Self- identify as Aboriginal/Torres Strait Islander; “have an existing chronic disease 
or are at risk of chronic disease, and in the opinion of the prescriber  would experience setbacks in the 
prevention or ongoing management of chronic disease if they did not take the prescribed medicine and  
are unlikely to adhere to their medicines regimen without assistance through the Measure”. 
16 Kelaher M, Dunt D, Taylor-Thomson D, Harrison N, O'Donoghue L, Barnes T, Anderson I. Improving 
access to medicines among clients of remote area Aboriginal and Torres Strait Islander Health Services. 
Aust N Z J Public Health. 2006 Apr;30(2):177-83 
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program (and QUMAX) on the other hand, are integrated with other programs providing 
QUM support and in the case of QUMAX- dose administration aids (see TOR (b)).   
Another difference between CTG scripts and the S100 supply program is that co-payment 
relief provided under S100 is not based on a patient’s ethnicity. Program eligibility for 
S100 is defined by the nature of the service (ie clients attending RAAHSs (which include 
ACCHSs).  
In this way, the S100 program simplifies the provision of PBS medicines, as the vast bulk 
of patients attending RAAHSs are Aboriginal or Torres Strait Islander. There is no limit 
to the amount of bulk supplied medicines which can be ordered from community 
pharmacies under S100.  
There is also no limit to the number of CTG scripts private general practices throughout 
Australia can provide to Australians who self-identify as Aboriginal or Torres Strait 
Islander. The eligibility criteria are flexible to account for a wide range of patient 
circumstances and co-payment relief can be provided for any PBS-listed medicine. For 
example, patients who are deemed to be ‘at risk of’ a chronic disease include those with 
family history and other environmental and socially determined factors including 
smokers, and those with low levels of physical activity.    
This means that any remote area patient identifying as Aboriginal or Torres Strait 
Islander can access co-payment relief for PBS medicines from one of two schemes – the 
S100 supply program (from RAAHSs) or through CTG scripts (from private general 
practices registered with the Indigenous PIP).  
At present, ACCHSs in remote locations cannot provide both CTG scripts and medicines 
under S100 (Table 3), nor have they been offered a choice. For remote Australia, there 
are obvious limitations to CTG scripts, in that there are few community pharmacies to 
offer these services. However, where a community pharmacy and private general practice 
are located in RRMA 6-7 regions, such services should be eligible to annotate CTG 
scripts. 
As a result of the CTG measure, Aboriginal patients no longer need to attend a RAAHS 
or ACCHS to receive affordable medicines. Increased affordability is important, but as 
vehicles for improving patient’s medication adherence and QUM, ACCHSs provide 
significant advantages over private general practices. This is an important point and is 
referred to in response to TOR (b) and (c).  
Several ACCHSs in RRMA 6-7 locations consulted by NACCHO indicated that they 
would definitely seek to annotate CTG scripts if they were given the option. The reasons 
given included: 
• Many clients travelling from remote to RRMA 4-5 locations and the need for these 
patients to access subsidised medicines through the CTG measure; 
• One ACCHS reported being “tied to S100” as there is no access to any other co-
payment subsidy program; 
• stock control responsibilities being a burden versus the simplicity of CTG scripts.  
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Table 3: Relationship between S100 and PBS Co-pay Relief Program according to 
type and location of practice.  
Category of 
services 
Location Invited to 
participate 
in 
Indigenous 
PIP? 
Need Indigenous PIP 
participation to 
annotate scripts 
‘CTG’? 
Can write 
CTG 
script? 
Can 
access 
QUMAX? 
Can 
access 
S100? 
Private general 
practices 
Australia-
wide 
Yes Yes Yes No No 
ACCHS  
(plus other IHSs)  
Non-remote  Yes No Yes Yes  
(only ACCHSs) 
No 
ACCHS  
(plus other IHSs)  
(ie RAAHS) 
Remote Yes No No No Yes 
ACCHSs: Aboriginal Community Controlled Health Services, IHS: Indigenous Health Service, RAAHS: 
Remote Area Aboriginal Health Services, QUMAX: Quality Use of Medicines Maximised for Aboriginal 
and Torres Strait Islander Peoples, PIP: Practice Incentives Program, CTG: Close the Gap. 
 
RECOMMENDATIONS 
• The supply of PBS medicines to RAAHS through S100 has substantially increased 
medicines access to the Aboriginal and Torres Strait Islander population in RRMA 6-7 
regions, and should continue to be the predominant form of medicines supply to these 
services.  
• Despite the gains in PBS utilisation from the S100 program, NACCHO does not 
believe that current expenditure in the S100 program is sufficient to meet Aboriginal 
people’s health needs. PBS utilisation may need to increase substantially (and exceed 
that for the non-Aboriginal population) to address the three times higher rate of death 
before age 65 years. 
• At present, remote area ACCHSs cannot offer clients both CTG scripts and PBS 
medicines under S100 (Table 3). Where a community pharmacy and private general 
practice are located in RRMA 6-7 regions, Aboriginal patients no longer need to 
attend a RAAHS or ACCHS to receive affordable medicines. Increased affordability is 
important, but as vehicles for improving patient’s medication adherence and QUM, 
ACCHSs provide significant advantages over private general practices (see TOR(c)). 
It is preferable for Aboriginal patients to have access to QUM supports. 
• ACCHSs in RRMA 6-7 locations should therefore be given the option of also 
providing CTG scripts to clients as well as the option to stock medicines on site 
through the S100 program.  
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(b)  the clinical outcomes achieved from the (s100) measure, in particular to 
improvements in patient understanding of, and adherence to, prescribed 
treatment as a result of the improved access to PBS medicines; 
The response to TOR(a) has established that affordability is a major factor in Aboriginal 
peoples equitable access to medicines and by addressing that, the S100 supply program 
has accomplished significant gains towards equity.  
However, patient’s adherence to medicines is mitigated by a variety of factors and not 
just cost- including demographic (age, sex, etc), psychosocial (beliefs, motivation, 
cultural), social disadvantage, health literacy, health system factors (type of service, 
social supports etc), and aspects related to the medicine itself.17 Many of these factors are 
addressed in QUM initiatives (see TOR (c)). 
Part of the success in the S100 program is related to the provision of medicines within the 
context of comprehensive culturally appropriate primary health care (especially through 
ACCHSs). The CRC Review (2004) confirmed that cultural appropriateness in the S100 
program (accessing medicines from an Aboriginal health service, and having Aboriginal 
people involved in dispensing) was a significant factor that improved medication 
adherence for Aboriginal clients.18  
The S100 program however, does not provide funding for Dose Administration Aids 
(DAA) nor their weekly refill. DAAs are commonly used medication management 
devices that lead to improved quality of life and better health outcomes for patients 
through improved quality use of medicines. Along with regular pharmacy interaction, 
DAAs can reduce adverse drug events and improve the patient’s ability to manage their 
medicines.2  
In the absence of a DAA funding scheme, at great expense, these costs have usually been 
borne by the ACCHSs themselves. The CRC Review (2004), recommended funding for 
DAA’s so that RAAHSs can use them in the S100 program.19   
More recently, the QUMAX program for non-remote ACCHSs has supported the cost 
borne by ACCHSs and delivered considerably more DAA’s to Aboriginal clients. Within 
12 months, 74,122 DAA’s had been dispensed through ACCHSs in non-remote areas to 
Aboriginal patients (2009-10)20 with substantial benefits in patient’s medication 
adherence:  
“Amongst the services and pharmacists that had been ‘operational’ for some time, there was a very 
consistent view that medication compliance had improved drastically. One person said 
                                                            
17 Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: A review from the 
patient's perspective. Ther Clin Risk Manag. 2008 Feb;4(1):269-86 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2503662/ 
18 Kelaher M, Taylor-Thomson D, Harrison N, O’Donoghue L, Dunt D, Barnes T & Anderson I. Evaluation 
of PBS Medicine Supply Arrangements for Remote Area Aboriginal Health Services Under S100 of the 
National Health Act. Melbourne (VIC): Co-operative Research Centre for Aboriginal Health & Program 
Evaluation Unit, University of Melbourne; 2004. page 96.  
19 Ibid. Page 18.  
20 Urbis Pty Ltd for the Australian Government Department of Health and Ageing. Evaluation of the 
Quality Use of Medicines Maximised for Aboriginal and Torres Strait Islander People (QUMAX) Program. 
April 2011. page 56 
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‘…compliance like we have never seen before.’ One pharmacist estimated that the rate of ‘pick 
up’ for repeat prescriptions had improved by 90%. ACCHSs claimed that they had noticed a 
strong improvement in people’s propensity to return to the service when they needed a new 
prescription for medications. Particular note was made of the impact of DAAs. For some services, 
QUMAX had allowed far greater use of Webster Packs etc without placing a financial burden on 
patients, pharmacies or ACCHSs. It was this increase in DAA use that was thought to lay behind 
the increased compliance that was being observed.”21  
An equally positive impact on medication adherence could be achieved through ACCHSs 
in remote areas if funding for DAA’s was provided to supplement the S100 Program.  
However, incorporating DAA fees into pharmacist handling fees in the provision of bulk 
medicines supply to RAAHSs may be difficult. A bulk order is not linked to individual 
patient’s prescriptions.  
 
RECOMMENDATIONS: 
• Affordability is a major factor influencing Aboriginal peoples equitable access to 
medicines and by addressing that, the S100 supply program has accomplished 
significant gains towards equity. Medication adherence is also influenced by a range 
of other factors and can be enhanced through QUM strategies (see TOR (c)) including 
dose administration aids (DAA’s). The S100 Program does not provide funding 
support for DAA’s and many ACCHSs pay for these through their core budgets. 
• NACCHO believes it is vital that financing for DAA’s to Aboriginal clients of remote 
area ACCHSs be supported in order to improve Aboriginal people’s medication 
adherence. 
• DAAs for remote area ACCHSs may be financed through: 
o a program such as QUMAX extended nationally, and/or other DAA 
program financed by extension to the 5th Community Pharmacy 
Agreement.  
o a DAA service similar to that provided by the Department of Veterans 
Affairs (DVA) for eligible clients funded by the Australian Government. 
o specific QUM related grants (a service-specific QUM budget including for 
DAAs) to ACCHSs. See TOR (c).  
 
 
 
                                                            
21 NACCHO Annual Report 2008-09. Page 34. 
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(c) the degree to which the ‘quality use of medicines’ has been achieved, including 
the amount of contact with a pharmacist available to these patients compared to 
urban Australians; 
 
Quality Use of Medicines means ensuring that “medicines are used wisely, safely and 
effectively”, while also ensuring the “safe storage and appropriate stock control of 
medicines.”22  The National Prescribing Service defines QUM as shown in Box 1. 
 
Box 1. Definition of the Quality Use of Medicine (NPS) 
Quality use of Medicines defined: 
For an individual, it means using (or not using) medicines appropriately, safely and effectively and having 
the knowledge and tools to do so 
For health professionals, it means: 
• choosing the most appropriate and cost effective treatment; and 
• giving people the knowledge and skills to use medicines to their best effect 
For providers of health services and products, it means contributing to best practice through appropriate 
information, education and promotional activities 
For governments, it means developing public policy, health systems, regulation and education that support 
best medicines use.23 
 
There is no doubt that the S100 Program has enhanced Aboriginal people’s access to 
medicines through bulk supply and co-payment relief, but through a range of ancillary 
programs, QUM within ACCHSs and other RAAHSs has also improved. 
There are several ways in which QUM support to ACCHSs and other RAAHSs accessing 
the S100 Program has evolved. The following is an incomplete list of QUM programs 
linked in some way to the S100 program. Reference is also made to the QUM program 
being delivered to non-remote ACCHSs (QUMAX) which has been found to be highly 
successful.   
1. S100 Support Allowance (Pharmacy Guild- Australian Government Community 
Pharmacy Agreement) 
2. Rural and Remote Workforce Program (Pharmacy Guild- Australian Government 
Community Pharmacy Agreement) 
3. Outreach Pharmacists for Remote Aboriginal Health Services (OPRAH- National 
Prescribing Service) 
4. Training of AHWs in QUM (Good Medicines Better Health Program) 
5. QUM Support under QUMAX 
  
Section 100 Support Allowance 
                                                            
22 National Aboriginal Community Controlled Health Organisation. Section 100 Pharmacy Support 
Program. Australian Government Department of Health and Ageing. 2 p. 
23 http://www.nps.org.au/about_us/what_we_do/about_quality_use_of_medicines 
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The Support Allowance was developed after the success of a joint pilot program 
undertaken by the Pharmacy Guild, NACCHO and Charles Sturt University which 
commenced in 1999 and was designed to enhance the QUM within ACCHSs.24 
Between 2005-10, the S100 Support Allowance Program ($13.4 million) under the 4th 
Community Pharmacy Agreement (CPA) provided an allowance of between $6000 and 
$10,500 per annum to community pharmacies for a range of QUM related services to 
support RAAHSs in ‘the implementation or continuation of S100 supply arrangements’.25 
26  
Under the 4th Agreement, the Business Rules were revised in collaboration with 
NACCHO so as to increase the collaborative relationship between ACCHSs (and other 
RAAHS) and community pharmacy. 
According to the revised Business Rules for this program, community pharmacy services 
to RAAHSs should include: 
• Developing and implementing an annual workplan in agreement with the CEO of 
the RAAHS formed after conducting an onsite needs assessment (templates 
available); 
• 6-monthly progress reports against the workplan (discussed with the CEO of the 
RAAHS and co-signing a “Continued Support Service Form”) provided to the 
Department of Health and Ageing (DOHA); 
• Providing assistance in the implementation of appropriate procedures and protocols 
for managing S100 supply arrangements, including the establishment of a medicine 
store; 
• Developing a range of other appropriate measures to enhance QUM (which may 
include assistance with dose administration aids, participation in regular meetings 
with health staff, and review of patient medication); 
• Implementing agreed measures which aim to enhance the QUM; and 
• Providing a range of education services to RAAHS clinical and support staff 
relating to medicines and their management. 
As part of the contractual agreement, the pharmacist is expected to consult with clinic 
staff to provide assistance in the following QUM areas: 
• Supply of medicines and maintaining adequate stock levels 
• Education of health service staff 
                                                            
24 Emerson, L., Bell, K., Croucher, K. Quality Use of Medicines in Aboriginal Communities Project: Final 
Report. Canberra: Pharmacy Guild of Australia.  (2001). 
25 The Australian Government Department of Health and Ageing & The Pharmacy Guild of Australia. 
Pharmacy Information Kit: Section 100 Pharmacy Support Allowance Program (Section 1). Canberra 
(ACT): Commonwealth of Australia; 2008. 10 p. 
26 The Pharmacy Guild of Australia. Review of the Existing Supply and Remunerations Arrangements for 
Drugs Listed Under Section 100 of the National Health Act 1953: Aboriginal Health Services Remote 
Access Program. Australian Healthcare Associates; 2010 Feb. 31 p. 
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• Drug information services 
• Management of DAA’s (e.g. Dosette boxes and Webster Paks) 
• Review of medication charts 
• Home Medication Reviews 
• Client counseling. 
The current allowance is based on the volume of PBS medicines supplied under the S100 
Program to the RAAHS in the preceding year, plus an additional travel loading.  
Two reviews recently appraised this program with the findings summarized below. A 
separate review examined the delivery of pharmacy services to RAAHSs, and is also 
referred to below. 
1. Australian Healthcare Associates Review27 
The Review found that: 
• the current Allowance does not reflect the level of effort required by the 
pharmacist, with these medical professionals often undertaking lengthy 
visits to AHSs to see patients; 
• the scheme poses a financial burden on some pharmacies; 
• there is difficulty in enlisting a locum to cover their absence at the 
pharmacy, have led in some instances to fewer visits than they consider 
necessary to provide an adequate service;  
• there is little use of new technology such as tele-pharmacy (using web 
cameras or videoconferencing); 
• However, many RAAHSs were requesting and receiving more than two 
visits per year (some received daily, weekly, fortnightly visits whilst others 
received one annual visit). 
The Review recommended that: 
• The support allowance funding might be better integrated with S100 medicines supply 
arrangements and that this be managed by a committee that was responsible for both 
areas.  
• They also recommended increased handling fees (this was increased from $1.55 to 
$2.69 per item in 2009, and again to $2.79 in 2011), plus separate fees for transporting 
and cold chain costs, which might be reimbursed based on receipts.  
• The 5th CPA to provide for additional fees for DAA provision to RAAHSs. 
• The 5th CPA provide set-up funds to RAAHSs if they require additional software 
programs to allow for electronic ordering. 
                                                            
27 Australian Healthcare Associates. Review of the existing supply and remuneration arrangements for 
drugs listed under Section 100 of the National Health Act 1953. Feb 2010. 
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• RAAHSs should be allowed to employ pharmacists with possible reimbursement 
through Medicare Australia; and  
• Allow pharmacists to be employed by RAAHSs and exempt RAAHSs from pharmacy 
location rules28 if these were to apply. 
Legislation inhibits pharmacists in most States from dispensing outside a registered 
pharmacy. Thus, career/academic pharmacists employed by the RAAHS, who do not 
want to own a pharmacy, are legally unable to label/dispense medicines or pack a DAA, 
or receive remuneration for this service through regular channels. An exception to this 
exists in the NT. 29   
As a result, the Review reported that RAAHSs “currently perform the labeling and 
dispensing services but do not receive reimbursement for this service. If funding was 
provided to [RA]AHS, this could be used by each [RA]AHS to improve their medicine 
storage facilities and increase members skills in performing these duties.”30 However, no 
recommendation was made in the report on this matter.  
The Review noted the difference between the S100 program handling fee ($2.69) and the 
PBS dispensing fee ($6.42) per item, and elicited a range of views regarding allocation of 
the underspend (if it was to be made available). These ranged from allocating this to the 
S100 Support Allowance to increase QUM support to RAAHSs, or funding other 
activities and initiatives for QUM.  
It is very clear that the S100 Program “has moved the responsibility for the management 
of the medicines storeroom, distribution of medicines and the provision of ongoing client 
information from pharmacists to [RA]AHS workers”31 and this has been welcomed by 
many services whilst also a burden for others.  
This situation has led to a range of strategies by ACCHSs such as employment of 
contractual pharmacists (see later), training of Aboriginal Health Workers as medicine 
assistants (see TOR (f)) and calls by RAAHSs to be eligible for access to the CTG scripts 
measure (see TOR (b)). 
 
                                                            
28 Pharmacy Location Rules have been a feature of all five Community Pharmacy Agreements and have 
been in place in one form or another since 1991. The Rules are given their effect by means of a Ministerial 
Determination under section 99L of the National Health Act.  This Determination, entitled National Health 
(Australian Community Pharmacy Authority Rules) Determination 2006 , is commonly referred to as the 
Pharmacy Location Rules (the Rules).  The Rules are administered by the Australian Community Pharmacy 
Authority (ACPA)… The Minister for Health and Ageing has a discretionary power to approve pharmacies 
in unique circumstances where the application of the location rules results in a community being left 
without reasonable access to the supply of pharmaceutical benefits by an approved pharmacist, and 
approval of the pharmacy is in the public interest. 
http://www.guild.org.au/5CPA/Initiatives/Location_Rules/Location+Rules.page 
29 Swain L. Remote Rural Pharmacists Project. Australian Pharmacy Council, June 2009. 
30 Australian Healthcare Associates Page 36.  
31 Australian Healthcare Associates  Page 42. 
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2. Nova Review32  
This Review surveyed 25 RAAHSs and found that they valued the S100 Support 
Allowance program as it addressed several QUM issues, especially with regard to safe 
storage, handling, dispensing and improved labeling of medicines. Pharmacists also 
generally concurred with these benefits. However, the program fails to provide sufficient 
pharmacist involvement in clinical activity such as medication chart reviews, and home 
medicines review.  
Importantly, the new Business Rules and workplan process were valued by almost all 
RAAHS, with support for “improving the efficiency of this process through online 
reporting.”33  
Recommendations for improvements to the program included: 
• Better sharing of information between participants utilizing the S100 Support 
Allowance (an action to be shared between the Pharmacy Guild and NACCHO) 
• Establish a governance mechanism to coordinate the program through the DOHA, 
Pharmacy Guild and NACCHO (including a complaints process). 
• More guidance for pharmacists in the provision of support to RAAHSs 
• Transferring responsibility for payment of pharmacy services to RAAHSs might 
enhance pharmacists accountability (eg cashing out existing subsidies for direct 
employment of pharmacists by RAAHSs) 
• Improvements to workplan reporting mechanisms (eg online submission etc) 
• Subsidies for RAAHSs for purchase of labeling equipment (The Review found many 
RAAHSs lacked labeling equipment). 
• Funding pool for QUM training of RAAHSs staff,  
• Subsidies for Dose Administration Aids. 
Some RAAHSs directly employed pharmacists (see Rural Workforce Pharmacy Program 
below). Direct employment significantly advantaged primary care delivery.  
The review referred to the potential for improved administration of the program such that 
it aligned with QUMAX. Moreover, the Pharmacy Guild recommended a full time 
position within NACCHO could be established to promote the program and its quality 
assurance to RAAHSs.34  
3. Australian Pharmacy Council Review35 
This review examined the legislative and remuneration barriers facing the delivery of a 
full range of pharmacist services in rural and remote regions but also through the S100 
supply program involving RAAHSs. 
                                                            
32 Nova Public Policy Pty Ltd.  Evaluation of Indigenous Pharmacy Programs. Final Report. 28 June 2010.  
33 Nova Review. Page 3 
34 Nova Review. Page 30.  
35 Swain L. Remote Rural Pharmacists Project. Australian Pharmacy Council, June 2009.  
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The review recommended: 
• Registering remote health clinics as ‘pharmacy outstations’ so that pharmacists may 
dispense in these locations. (Including also the labeling, packing of DAAs, provision of 
medication counseling and other pharmacy services). This would require legislation 
amendments, and there is a precedent in the NT.36 
• Remunerating remote pharmacists for services though the Medicare Benefits Schedule 
(MBS). Services to be considered include: medication counseling, patient case 
conferences with Medical Practitioners, (face to face or by phone), Home Medicines 
Review (already existing), Nurse and Aboriginal Health Worker medication education.  
• Exempting RAAHSs from pharmacy ownership laws if a pharmacist is employed full 
time to oversee and establish QUM observance. 
• For the Federal Government to employ and suitably remunerate a pharmacist for each 
[RA]AHS.  
• Aligning, simplifying and revising State Health Poisons Acts and Pharmacy Practice 
Acts legislation. 
 
Rural Pharmacy Workforce Program (RPWP) 
This 4th Community Pharmacy Agreement program is managed by the Pharmacy Guild 
and one function is to provide pharmacy academics at 11 University Departments of 
Rural Health ($3.2m).37 As well as managing rural clinical placements for pharmacy 
students (including within ACCHSs), these academic pharmacists also deliver OPRAH 
(see below) and can be employed also within ACCHSs for S100 QUM support.    
For example, in the Kimberley region of WA, the S100 Support Allowance is redirected 
(by contract with the pharmacist) to the Kimberley Aboriginal Medical Services Council 
(KAMSC), which then employs their own pharmacist to deliver these QUM services 
according to the business rules of the Allowance. Funding for an academic pharmacist 
from the University Departments of Rural Health provides additional funds to 
supplement the cost of this QUM provision.  
According to the Australian Healthcare Associates Review: “there is also nothing to 
preclude a community pharmacist from engaging a consultant/academic pharmacist 
through a local agreement to undertake the RAAHS [S100 support allowance services]… 
Nevertheless some consultant pharmacists would like to be able to access the Allowance 
in their own right, and not be contracted by a community pharmacy.”38  
A recent review of the RPWP did not explore this role further.39 
                                                            
36 Dispensing by pharmacists permitted in NT RAAHSs under Health Minister approved exemption of 
Section 94 of the Health Act. [Source: Swain review].  
37 Note that funding for the pharmacy academics is provided to the Universities, not direct to the UDRH. 
38 Australian Healthcare Associates Review. Page 38.  
39 KPMG. Evaluation of the Rural Pharmacy Programs Final Report. Department of Health and Ageing. 
Nov 2010. 
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There is also a number of small projects underway funded under the RWPP that aim to 
develop career pathways for Aboriginal people to provide medication support services in 
remote AHS settings, or to pilot the role of Aboriginal adherence workers.40 (see also 
TOR (f)). 
 
Outreach Pharmacists for Remote Aboriginal Health Services (OPRAH) 
This program is funded by the National Prescribing Service (NPS) and aims to enhance 
QUM by training those pharmacists who provide support to RAAHSs to deliver QUM 
education to clinic staff (nurses and Aboriginal Health Workers- AHWs). Training 
sessions are conducted twice yearly, and educational sessions to RAAHSs are offered on 
two topics annually. 
Pharmacists can report on this activity in the workplans developed under the S100 
pharmacy support allowance, minimising any additional burden to participants. 
Moreover, it permits networking of pharmacists supplying S100 bulk supply to 
RAAHSs.41 
In 2009, 29 outreach pharmacists were trained who in turn delivered QUM training for 
‘chronic obstructive pulmonary disease’ at 33 RAAHSs to 106 staff including 38 AHWs 
and 52 nurses.42   
 
Training of AHWs in QUM (Good Medicines Better Health Program- GMBH) 
Funded by the National Prescribing Service (NPS), this program is a national joint 
initiative between NACCHO, the State Affiliates associated with the rollout of GMBH, 
and various training organisations. The program’s goal is to enhance Aboriginal Health 
Workers (AHWs) capacity to provide QUM support to clients of ACCHSs across 
Australia.  
Affiliates or training organisations provide modular training to AHWs who then train 
other workers within their services including RAAHSs. Training is accredited towards 
AHW Certification (IV). Approximately 60 AHWs are expected to complete training as 
‘trainers’ over three years to 2013-14.  
 
QUM Support under QUMAX 
The QUMAX program for ACCHSs has successfully embedded QUM within non-remote 
services, in conjunction with the CTG scripts measure. An independent review confirmed 
                                                            
40 KPMG. Evaluation of the Rural Pharmacy Programs Final Report. Department of Health and Ageing. 
Nov 2010.  
41http://www.nps.org.au/news_and_media/media_releases/repository/Supporting_outreach_pharmacists_ac
ross_Australia 
42 Pippa Travers-Mason, et al. Getting QUM messages on COPD into remote Aboriginal Health Services- 
how OPRAH did it? NPS 2010. 
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that QUMAX has substantially improved the capacity of ACCHSs to deliver QUM.43 
Box 2 and 3 summarise the features of the program. 
The successes achieved with QUMAX may help inform the systematic application of 
QUM within RAAHSs participating in the S100 program. A joint QUMAX and S100 
Support program workshop involving pharmacists and ACCHSs (plus other RAAHSs) is 
proposed to be held later this year to share learning’s on QUM and consider possible 
improvements to the S100 program. 
 
Box 2. Summary of how Quality Use of Medicines Workplans are developed 
through the QUMAX Program 
How QUMAX Works 
ACCHSs are enabled and supported to deliver QUM through an electronic and coordinated workplan – 
based system. ACCHSs agree to an annual joint workplan with a range of community pharmacies. The 
activities are costed and agreed upon, based on a financial grant allocated to each participating service.  
Grants depend on the size of the clinics (number of registered clients in the ACCHS) and range from 
$10,000 to $87,000 per annum. Workplans are then jointly approved by the Guild and NACCHO Program 
Managers as well as Department of Health & Aging representative. ACCHSs are funded by the Guild 
through contracts containing the workplans. At the same time, the Pharmacy Guild provides pharmacists 
up-front quarterly funding for the DAA costs based on the agreed workplan.  
There is 100% participation by all ACCHSs in non-remote locations throughout Australia (73 ACCHSs). 
Support for QUM is sourced by ACCHSs from their local nominated community pharmacists as well as a 
funded State-based QUM Support Pharmacist/s employed by the Pharmacy Guild.  NACCHO State 
Affiliates also receive funding from NACCHO to provide support to ACCHSs in their own jurisdiction for 
QUM related activities.  
Individual ACCHSs can also appoint sessional pharmacists (by allocating their ‘QUM pharmacy support’ 
option accordingly) to undertake QUM activity. Pharmacists from community pharmacies can agree to 
undertake this work, or the ACCHSs may make alternate arrangements if the community pharmacist is 
unavailable. These appointments will be approved by the Department of Health and Ageing on a case by 
case basis.   
 
Box 3. Summary of the range of customized and service-specific QUM related 
activities that can be undertaken through the QUMAX Program 
The QUM activities funded through QUMAX include: 
• DAA provision. 
• QUM pharmacy support (eg safety net education, QUM training for staff/clients, brokering access to 
NPS or other QUM programs, promoting Home Medicine Reviews to clients such as elders, advice on 
medicine stock control, sessional employment of a pharmacists, etc) 
• HMR models of support (eg establishing specific MHR protocols for the ACCHSs, reimbursement for 
service orientation provided to the HMR pharmacist, health promotion clinics, reminders for HMR 
visits, accompanying AHWs to HMR visits) 
• QUM devices to improve medication delivery (eg asthma spacers,44 point of care testing etc) 
                                                            
43 Urbis Pty Ltd, Review, 2011. 
44 In conjunction with the Asthma Spacers Ordering Scheme. 
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• QUM education  
• Cultural awareness (eg reimbursement to ACCHSs for cultural training to pharmacies)  
• Transport support (eg to assist patients getting to a pharmacy for filling of scripts) or for delivery of 
scripts or medicines). 
 
Many of the aforementioned reviews have highlighted the need to enhance the provision 
of pharmacist services to RAAHSs and a role for an academic or career pharmacist.  
Recently, the new ‘Pharmacist Coalition for Health Reform’ expressed concern their 
services were being underutilized and will push for a role in different models of care.45 
Such models include salaried and sessional positions for pharmacists alongside other 
primary care staff.46  
The National Health and Hospitals Reform Commission (NHHRC, 2009) report,47 
signaled some future reforms “within GP-led medical centres which could function as 
‘one-stop shops’ and include, not only general practitioner and nursing care but also 
access to a range of additional services including pharmacies."48 However, reforms to the 
role of pharmacists were not specifically addressed. 
These developments are consistent with the views of RAAHSs which recommend 
pharmacists to be employed within RAAHSs.  
A possible enabling strategy for such a role is through the new Practice Nurse Incentive 
Program (PNIP). The program was announced in May 2010, and aims to contribute 
$390.3 million to general practices and ACCHSs to employ practice nurses and/or 
Aboriginal Health Workers per full time equivalent GP. This measure will support 
Aboriginal Community Controlled Health Services throughout Australia, and general 
practices in urban areas where there are workforce shortages. 
Funding will allow ACCHSs to employ a part-time allied health professional, such as a 
physiotherapist, dietician and occupational therapist, instead of, or in addition to, a 
practice nurse and/or Aboriginal Health Worker. The DOHA has listed the types of allied 
health professional eligible under this measure; however, NACCHO noted that 
‘pharmacists’ and ‘dentists/ assistants’ were not listed. 49  
NACCHO strongly recommended that the program rules be amended to permit the 
inclusion of pharmacists for when the PNIP starts on 1st July 2011, but the rules have not 
                                                            
45 Kelly J. Pharmacists want reform role. The Australian 20 June 2011. Page 7.  
46 Pharmacist Coalition for Health Reform Media release: National pharmacist organisations work together 
to input to health reform agenda, 17 Nov 2010. 
http://www.napsa.org.au/documents/PCHR_media_release_17_Nov_2010.pdf 
47 A healthier future for all Australians, 
48 RPWP report 
49 National Aboriginal Community Controlled Health Organisation. Meeting of the Practice Nurse 
Incentive Program Technical Working Group. National Aboriginal Community Controlled Health 
Organisation; 2010 Dec. 3 p. 
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changed. It is vital this measure be amended to include pharmacists as part of the 
expanding primary care team.  
 
RECOMMENDATIONS:  
• The S100 supply of medicines to ACCHSs has evolved to encompass a range of 
ancillary programs that support the quality use of medicines (QUM). The often 
unconnected nature of these programs adds to their complexity for primary health care 
services. These programs need better integration within primary health care. This can 
be achieved by the introduction of a scheme to allocate QUM budgets to ACCHSs 
from which services can draw from, and negotiate service-specific activities with 
community pharmacy or academic pharmacists. The difference between the S100 
program handling fee ($2.79) and the PBS dispensing fee ($6.42) per item comprises a 
PBS underspend that could be used to fund a range of service specific QUM initiatives 
within remote area ACCHSs. 
• Governance for the broad range of QUM programs established to support RAAHSs in 
the S100 program needs to be improved.  
o This will require the establishment of a broader and multidisciplinary 
steering committee structure that has significant NACCHO membership, 
but also includes the involvement of a range of pharmacy groups.  
o In addition, consideration should be given to integrating or creating cross 
membership between remote-area QUM governance structures with 
governance committees responsible for QUMAX and the CTG PBS co-
payment relief measure (CTG scripts).  
o NACCHO should be invited to be a member of a governance structure to 
monitor the implementation, uptake and evaluation of the CTG scripts 
measure, especially in the disaggregation of data between ACCHSs and 
private general practices.  
• Multiple independent reviews have confirmed that a greater level of pharmacist 
involvement in RAAHSs is needed. RAAHSs should be supported to employ salaried 
and sessional positions for pharmacists alongside other primary care staff. This can be 
achieved by transferring responsibility for the payment of QUM related pharmacist 
services to RAAHSs, as they move towards adopting pharmacists as core members of 
the primary health care team. Funding sources for these positions needs to be agreed 
and a range of options considered.  
• NACCHO recommends that ‘pharmacists’ be added as additional allied health 
professionals under the Practice Nurse Incentive Program (PNIP). This will provide 
the option for ACCHSs to (partly) fund a pharmacist (in any location across 
Australia).  
• Introduce Medicare Rebates for the delivery of pharmacist services within ACCHSs 
(remote and non-remote) in recognition of their role within the primary health care 
team. This would support the full/part-time employment of pharmacists to undertake 
QUM related services and training.  
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• By expanding existing workforce related schemes, funding provision could be made 
for more academic pharmacist employment within remote-area ACCHSs. Examples of 
schemes include the Rural Pharmacy Workforce Program under the 5th Community 
Pharmacy Agreement; and amendments to the Practice Nurse Incentive Program (by 
introducing pharmacists in the allied health professional category). 
• Introduce a scheme for Medicare Australia to reimburse RAAHSs for dispensing S100 
medicines to their clients. The labeling and dispensing activity of RAAHSs is 
currently not reimbursed. ACCHSs undertake and fund this activity from core service 
budgets. Funding received under such a scheme could be used towards QUM activity. 
• Introduce a coordinated and systematic approach to QUM ‘systems support’ within 
remote area ACCHSs by enabling service-specific initiatives through QUM Budgets 
and online QUM workplan development.  QUM budgets (see above) could be used to 
subsidise the purchase of labeling equipment or provide QUM training of ACCHSs 
staff, or the employment of sessional pharmacists (or other uses of a service-specific 
QUM allocation- see Box 3). 
• Regional or State/Territory ‘QUM Pharmacists’ could be employed within Affiliates 
or by the Guild (as per the QUMAX Program) to provide local support to remote area 
ACCHSs in developing service-specific QUM workplans and allocating their QUM 
budgets. Such an approach would need further consultation with NACCHO, taking 
into account the role of pharmacists employed locally by ACCHSs.  
• A systematic and online approach to remote-area QUM workplan development would 
improve transparency, enhance workforce support, help ACCHSs to manage a service-
specific QUM related budget, improve accountability and Departmental feedback to 
ACCHSs, and provide more tools to help guide services in the specification of the 
QUM services they need at a local level. The successes achieved with QUMAX may 
help inform the systematic application of improved administration and monitoring 
towards QUM within ACCHSs participating in the S100 program.  
• The implementation of an improved administration and monitoring system towards 
QUM within ACCHSs would require a full time position to be funded within 
NACCHO to facilitate the establishment of the above quality assurance system.  
• NACCHO encourages the Senate Committee to recommend legislative amendments 
to: 
o overcome the current prohibition to dispensing/filling of Dose 
Administration Aids (DAA) by pharmacists outside a community 
pharmacy. (eg Registering remote health clinics as ‘pharmacy outstations’ 
was one suggestion, but the feasibility and acceptability of that would 
need investigation). 
o Align, simplify and revise State Health Poisons Acts and Pharmacy 
Practice Acts legislation so that barriers in the provision of pharmacy/ist 
services faced by RAAHSs can be addressed.  
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(d)  the degree to which state/territory legislation has been complied with in respect 
to the recording, labeling and monitoring of PBS medicines; 
There are statutory requirements for the labeling of prescription medicines being 
dispensed.50 Australian Guidelines for the content of labels on dispensed medicines is 
shown in Box 4. 
 
Box 4. Guidelines for labeling dispensed medicines. 51 
Guidelines for labeling dispensed medicines 
• The label should be clearly and legibly printed in unambiguous and understandable English;  
• The brand and generic names of the medicine, the strength, the dose form and the quantity supplied (for 
extemporaneously prepared medicines and medicines not dispensed by count, the name and strength of 
each active ingredient, and the name and strength of any added preservatives or the name of the formula 
as described in a standard reference book);  
• Specific directions for use, including frequency and dose 
• The patient’s name  
• The date of dispensing or supply the dispenser’s (and if different, the checking pharmacist’s) initials 
• A unique identifying code 
• The name, address and telephone number of the pharmacy or pharmacy department at which the 
prescription was dispensed  
• Storage directions (where important) and expiry date (where applicable) 
• The words ‘Keep out of reach of children’. 
 
The Nova Review recommended subsidies for RAAHSs for the purchase of labeling 
equipment, as the Review found many RAAHSs lacked labeling equipment.  
However, some ACCHSs (eg in the Kimberley region of WA) have no problems with 
labeling and monitoring of PBS medicines. 
The Kimberley Aboriginal Medical Services Council (KAMSC) operate a regional 
system of bulk medicine order and supply, with thermal labels generated through the 
electronic information management system MMEX (web-based e-health record). MMEX 
assists the pharmacist on site (employed as academic pharmacist and subcontracted 
through the S100 support allowance) to control stock and check on orders based on a 
Standard drugs list. Occasions of dispensing are recorded in MMEX, and accessed by 
doctors anywhere across Kimberley ACCHSs.  
 
RECOMMENDATION: 
                                                            
50 The general requirements for medicinal labels are detailed in the Therapeutic Goods Order No. 69, which 
falls under section 10 of the Therapeutic Goods Act 1989. Source: Commonwealth of Australia. 
Therapeutic Goods Order No. 69 – General Requirements for Labels for Medicines. Canberra (ACT): 
Office of Legislative Drafting and Publishing, Attorney-General’s Department; 2009 Apr. 
51 Pharmacy Board of Australia. Guidelines for dispensing of Medicines [undated].  
www.pharmacyboard.gov.au 
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• RAAHSs are required (under S100 supply) to dispense and label PBS medicines, and 
this function should therefore be supported by a QUM-related service-specific budget 
(see TOR (c)).   
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(e) the distribution of funding made available to the program across the Approved 
Pharmacy network compared to the Aboriginal Health Services obtaining the 
PBS medicines and dispensing them on its patients; 
Previous sections of this submission have described the S100 supply program and 
ancillary QUM program funding.  The distribution of funding through S100 supply 
program is a function of client demand from RAAHSs and is an uncapped Australian 
Government provision. Pharmacists and RAAHSs also benefit from other QUM related 
funding (such as the S100 Support Allowance, amongst other programs - see TOR(c)).  
Most of these QUM-related programs supporting S100 medicines supply are funded 
under the Community Pharmacy Agreement between the Australian Government and the 
Pharmacy Guild of Australia. Few QUM related programs have a direct funding 
relationship between the Australian Government and the ACCHSs sector.  
Because community pharmacies don’t dispense medicines directly to patients attending 
S100 sites (GPs, nurses and AHWs dispense within RAAHSs), they receive a lower 
dispensing fee per medicine from the PBS.  
The difference between the S100 program handling fee ($2.79) and the PBS dispensing 
fee ($6.42) per item comprises a PBS underspend that could be used to fund a range of 
service specific QUM initiatives within ACCHSs.  
This can be achieved by the introduction of a scheme to allocate QUM budgets to 
ACCHSs from which services can draw from, and negotiate service-specific activities 
with community pharmacy or academic pharmacists.  
 
RECOMMENDATION: 
See recommendations pertaining to TOR(c). 
 
  32
Submission from the National Aboriginal Community Controlled Health Organisation, June 2011 
(f) the extent to which Aboriginal Health Workers in remote communities have 
sufficient educational opportunities to take on the prescribing and dispensing 
responsibilities given to them by the PBS bulk supply arrangements; 
Aboriginal Health Workers (AHWs) do not prescribe medications. With regard to 
dispensing activity, Certificate IV level trained AHWs are trained to interpret medicine 
order’s accurately, administer medicines safely (including injections), understand and 
work within the legal framework for medicines use, support client’s use of medicines, 
and dispense medicines under standing orders as required amongst other QUM activity.  
All Registered Training Organisations (RTO) that offer the ‘Certificate IV in Aboriginal 
and/or Torres Strait Islander Primary Health care (practice)’ must deliver the 
HLTAHW406A Unit ‘Work with Medicines’ as it is a compulsory component of this 
training.  
The completion of Cert IV AHW training across Australia is now standardised and 
provides the skills set necessary for AHWs working with medicines in RAAHSs under 
the S100 supply program. Cert IV training provides 9 months of exposure to working 
with medicines within the clinic environment under supervision, and the completion of a 
3 week face to face unit in medicines theory including QUM. AHWs are also trained to 
fill DAA’s and label medicines.  
In the NT completion of the medicines module is a requirement of AHW CertIV 
Registration.  
The elements of training that will deliver essential outcomes of this Unit of competency 
include:52 
• Determining client medication requirements (contraindications of commonly used 
medication, maintain medication records, etc) 
• Interpreting orders and instructions for medication, and referring queries appropriately 
(including checking written and verbal medication instructions against published 
medicines information resources) 
• Supporting clients in their use of traditional and western medicines (identifying 
generic and brand names of medicines commonly used in Aboriginal health services, 
providing consumer medicines information, including dosing and side-effects, support 
clients in obtaining PBS medicines, etc). 
• Administer medicines safely (identifying dosages, giving injections, identifying 
adverse events, filling DAAs and labelling medicines in line with statutory 
requirements, maintain medicines records in line with legal requirements, etc). 
• Transport, store and dispose of medicines (storage and disposal according to 
legislative requirements and manufacturers, cold chain transport etc). 
Modules in the Good Medicines Better Health Program (joint NACCHO and the National 
Prescribing Service (NPS)) provide some of the modules used by AHWs in the Cert IV 
training delivered by RTOs. 
                                                            
52 Source: J Poelina. KAMSC School of Health Studies. Broome WA. [Accessed June 2011]. 
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A number of jurisdictions struggle to meet all the requirements of the Unit because of 
‘Poisons Acts’ regulations often restrict AHWs from administering medicines including 
paracetamol. However, expert consensus is that most AHWs in RAAHS utilising S100 
program would have the requisite skills and knowledge required to undertake these tasks. 
Work is also underway in the KAMSC School of Health Studies to develop accredited 
training towards ‘Medication Assistants’ whose role would be to undertake supervised 
dispensing activity and stock control.53 
But not all ACCHSs have adequately trained staff to undertake stock control, medicines 
labelling, and dispensing. One ACCHS reported that they had labelling equipment but no 
trained staff to use it. Another ACCHS reported having labelling equipment but the 
machine was unreliable, which meant labelling by hand. 
Such situations underscore the need for systematic and coordinated programs for 
supporting remote area ACCHSs, and their workforce, in QUM. 
  
RECOMMENDATIONS: 
• Legislative reform and QUM-budgets would assist staff within ACCHSs to undertake 
their required responsibilities towards dispensing and quality use of medicines. (See 
TOR(c)) 
• The employment of pharmacists within ACCHSs (see TOR(c)) would enhance 
educational opportunities for AHWs towards roles as Medication Assistants or the 
completion of Cert IV AHW Training. 
 
                                                            
53 Personal communication: Sabina Wakerman, KAMSC.  
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(g) the degree to which recommendations from previous reviews have been 
implemented and any consultation which has occurred with the community 
controlled Aboriginal health sector about any changes to the program; 
There has been limited consultation with the ACCHS sector regarding any reforms to the 
S100 supply program or in negotiations arising for the 5th Community Pharmacy 
Agreement (for S100 Support Allowance or rural workforce measures). 
The new business rules for the S100 support allowance under the 4th Community 
Pharmacy Agreement were developed in consultation with NACCHO and its 
State/Territory Affiliates, but there has been no further program consultation.  
NACCHO has had an excellent and long-term association with the Pharmacy Guild of 
Australia and the Department of Health and Ageing (DOHA)- both have partnered with 
NACCHO in the development and implementation of the S100 supply program, the 
Support Allowance, and the QUMAX program. 
However, there have not been any recent moves by the Pharmacy Guild or the Australian 
Government to substantially reform any of the S100 related programs. As described 
previously, over the years, the S100 supply of medicines to ACCHSs has evolved to 
encompass a range of ancillary programs that support the quality use of medicines 
(QUM) as well as their supply. The often unconnected nature of these programs adds to 
their complexity for primary health care services. These programs need better integration 
within primary health care and this can be achieved by the introduction of a scheme to 
allocate QUM budgets to ACCHSs from which services can draw from, and negotiate 
service-specific activities with community pharmacy or academic pharmacists (see TOR 
(c)).  
Most of the ACCHSs contacted by NACCHO in the preparation of this submission stated 
that they received little feedback from community pharmacies regarding progress with 
S100 (supply or support). ACCHSs reported to NACCHO that they almost never 
received a response from the DOHA regarding their workplans and that they had to 
actively seek an opportunity to give the DOHA some feedback. 
Through the Community Pharmacy Agreements process, pharmacies are the primary and 
often sole contact point with DOHA regarding the completion of S100 workplans with 
RAAHSs. This structure has created a large communication gap in that ACCHSs in 
remote areas are often disengaged from being active participants in reforming the 
program. There is a lost of scope for improved communication with ACCHSs in this 
program. 
 
RECOMMENDATION: 
• NACCHO believes that the substantial communication gap that prevents remote area 
ACCHSs from learning of the outcome of S100 support allowance workplans, and 
prevents feedback to the Department of Health and Ageing regarding the S100 supply 
program, can be resolved by the adopting the recommendations pertaining to TOR(c). 
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(h) access to PBS generally in remote communities;  
NACCHO makes the following additional recommendation: 
• NACCHO continues to support the evidence-based listing of medicines in the PBS 
specifically for the Aboriginal and Torres Strait Islander population.  NACCHO 
encourages the Department to invite NACCHO to consult with ACCHSs regarding 
any additional medicines that might be added to the PBS for this specific population. 
(i) any other related matters. 
N/A. See above.  
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3.0 Appendix 
 
Call for Submissions 
The effectiveness of special arrangements for the supply of Pharmaceutical 
Benefits Scheme (PBS) medicines to remote area Aboriginal Health Services 
Information about the Inquiry 
On 24 March 2011 the Senate referred the following matter to the Senate Community 
Affairs Committees for inquiry and report. 
Submissions should be received by 30 June 2011. The reporting date is 18 August 
2011.  
The Committee is seeking written submissions from interested individuals and 
organisations preferably in electronic form submitted online or sent by email to 
community.affairs.sen@aph.gov.au as an attached Adobe PDF or MS Word format 
document. The email must include full postal address and contact details. 
Alternatively, written submissions may be sent to: 
Committee Secretary 
Senate Standing Committees on Community Affairs 
PO Box 6100 
Parliament House 
Canberra ACT 2600 
Australia 
 
Terms of Reference 
The effectiveness of special arrangements for the supply of Pharmaceutical 
Benefits Scheme (PBS) medicines to remote area Aboriginal Health Services 
Terms of Reference 
The effectiveness of the special arrangements established in 1999 under section 100 of  
the National Health Act 1953, for the supply of Pharmaceutical Benefits Scheme  
(PBS) medicines to remote area Aboriginal Health Services, with particular reference  
to:  
 
(a) whether these arrangements adequately address barriers experienced by  
Aboriginal and Torres Strait Islander people living in remote areas of Australia  
in accessing essential medicines through the PBS;  
 
(b) the clinical outcomes achieved from the measure, in particular to improvements  
in patient understanding of, and adherence to, prescribed treatment as a result  
of the improved access to PBS medicines;  
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(c) the degree to which the ‘quality use of medicines’ has been achieved including  
the amount of contact with a pharmacist available to these patients compared to  
urban Australians;  
 
(d) the degree to which state/territory legislation has been complied with in respect  
to the recording, labelling and monitoring of PBS medicines;  
 
(e) the distribution of funding made available to the program across the Approved  
Pharmacy network compared to the Aboriginal Health Services obtaining the  
PBS medicines and dispensing them on to its patients;  
 
(f) the extent to which Aboriginal Health Workers in remote communities have  
sufficient educational opportunities to take on the prescribing and dispensing  
responsibilities given to them by the PBS bulk supply arrangements;  
 
(g) the degree to which recommendations from previous reviews have been  
implemented and any consultation which has occurred with the community  
controlled Aboriginal health sector about any changes to the program;  
 
(h) access to PBS generally in remote communities; and  
 
(i) any other related matters. 
 
